Search results
Results from the WOW.Com Content Network
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment . The company was founded in 1998 and went public in 2004.
The subcutaneous injection of atezolizumab and hyaluronidase was evaluated in IMscin001 (NCT03735121), an open-label, multi-center, international, randomized trial in adults with locally advanced or metastatic non-small cell lung cancer who were not previously exposed to cancer immunotherapy and who had disease progression following treatment with platinum-based chemotherapy. [2]
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Halozyme Therapeutics Inc (NASDAQ:HALO), with a market capitalization of US$2.2b, rarely draw their ...
For premium support please call: 800-290-4726 more ways to reach us
Halozyme Therapeutics has had an incredible year, rallying more than 100% since the beginning of 2013. However, the ride up has been a very bumpy one, due to two major developments involving its ...
Last week, two major events shook up the market for breast cancer treatments. Shares of Halozyme Therapeutics and Roche rose on the EU approval of subcutaneous Herceptin, while Eli Lilly fell ...
What: Shares of Halozyme Therapeutics , a. Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're ...
What: Shares of Halozyme Therapeutics , a. Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're ...